The percentage of patients aged 18 years and older with proteinuria who are taking an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.9 Care Setting
-
1.14 Numerator
Patients with a current fill for an ACE-I or ARB
-
1.15 Denominator
All patients aged 18 years and older with a urine protein >= 200 mg/g
-
Exclusions
Specific exclusions:
Patients with contraindication to an ACE inhibitor or ARB, including pregnancy, prior angioedema, hypotension, hyperkalemia, rising creatinine, chronic kidney disease stage 3-5 (without dialysis), aortic stenosis, hypertrophic cardiomyopathy, multiple myeloma with treatment, diabetes diagnosis, renal transplant, immunosuppresive therapy
Patient data confirming pregnancy/delivery, pregnancy planning, breastfeeding, hypotension, or refill for Aliskiren in the past 6 months
General exclusions:
• Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
• Patients who have been in a skilled nursing facility in the last 3 months
-
Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed Renal Endorsement Maintenance ProjectInitial EndorsementLast UpdatedRemoval Date
-
StewardSteward Organization Email
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)
-